Why Invest?
Corporate Overview
Founded in 1993 by Dr. Robert Foster, Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Its entrepreneurial management and world-class team of scientists are building a pipeline of immunosuppressive drug candidates for treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Isotechnika looks to become the leader in development of immunosuppressant therapies.
The Company announced successful completion of the PROMISE trial on May 27, 2008. As well, patients completing the six month trial were given the opportunity to continue treatment with voclosporin as part of an extension to the initial trial. This six month extension period will provide longer-term safety and efficacy data for the drug in de novo kidney transplant patients.
The second indication under development for voclosporin is for the treatment of plaque psoriasis. The Phase 3 psoriasis trial currently ongoing in Europe and Canada completed enrollment with 642 patients in July 2007. It is a 60 week, double-blind trial with both placebo and cyclosporine control arms. While efficacy can be determined as early as 12 weeks, the trial has been designed to remain blinded for the entire 60 week duration so that longer-term safety data remains unbiased. Final data is expected to be released in the first half of 2009.
On May 24, 2006, the Company signed an agreement with Lux Biosciences Inc. (Lux) granting them worldwide rights to develop and commercialize voclosporin for the treatment and prophylaxis of all ophthalmic diseases. Their most advanced development in uveitis has a worldwide market size of 500,000 patients. Positive Phase 3 results from the uveitis program were announced in March 2009. Lux received both "Fast Track" and "orphan" drug status for this indication. It is anticipated that Lux will file a New Drug Application (NDA) for uveitis in the near future and it will therefore likely be the first commercialized indication of voclosporin.
Isotechnika Inc. is publicly traded on the Toronto Stock Exchange under the symbol ISA.